Status:
COMPLETED
Efficacy of Resveratrol in Depression
Lead Sponsor:
Russian Academy of Medical Sciences
Collaborating Sponsors:
Russian Science Foundation
Conditions:
Depression
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HD...
Eligibility Criteria
Inclusion
- Inclusion Criteria (selectively):
- MDD recurrent or with single episode with melancholic features or dysthymia (DSM-5);
- current depression.
- Exclusion Criteria (selectively):
- serious or unstable disease;
- antidepressants intake.
Exclusion
Key Trial Info
Start Date :
July 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 18 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03384329
Start Date
July 4 2018
End Date
September 18 2019
Last Update
December 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lyubomir I. Aftanas
Novosibirsk, Russia, 630117